Form 4: Mirum Pharma SVP Sells Shares for Tax Obligations

Mirum Pharmaceuticals' SVP, Global Controller, Jolanda Howe, sold 926 shares of common stock to cover tax withholding obligations following the vesting of restricted stock units.

Summary

• Jolanda Howe, SVP, Global Controller, reported changes in beneficial ownership of Mirum Pharmaceuticals, Inc. common stock and restricted stock units.
• On January 21, 2026, 1,542 restricted stock units (RSUs) vested and converted into 1,542 shares of common stock.
• On January 22, 2026, 926 shares of common stock were sold at a price of $93.3252 per share.
• This sale was conducted to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Jolanda Howe beneficially owns 3,042 shares of common stock and 3,083 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral, routine insider transaction for tax purposes following RSU vesting. It does not indicate significant positive or negative sentiment about the company's prospects.

Positives

• The vesting of 1,542 restricted stock units indicates continued employee retention and long-term incentive alignment for a senior executive.

Negatives

• The sale of 926 shares by a senior executive, even for tax purposes, reduces their direct equity stake in the company.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedule of the remaining restricted stock units, which will continue over the next two years from the vesting commencement date.

Industry Context

This Form 4 filing is a routine insider transaction report, common across all industries, reflecting an executive's compensation structure and tax obligations upon RSU vesting. It does not provide specific insights into broader industry trends or competitive positioning for Mirum Pharmaceuticals.

Comparison to Industry Standards

• The transaction, involving the sale of shares to cover tax obligations upon RSU vesting, is a standard practice for executives across various industries, including biotechnology and pharmaceuticals.
• This is a common mechanism for managing equity compensation and associated tax liabilities.
• No specific comparable companies or projects are detailed in this transactional filing.

Stakeholder Impact

• Shareholders: A minor dilution effect from the RSU conversion, offset by the executive's continued equity holding. The sale for tax purposes is a routine event and generally not seen as a negative signal.
• Employees: The vesting of RSUs reinforces the company's long-term incentive program for its executives.

Next Steps

• The remaining 3,083 Restricted Stock Units will continue to vest in annual installments on January 21, 2027, and January 21, 2028, completing the three-year vesting schedule from the January 21, 2025, commencement date.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive sold shares to cover tax obligations upon RSU vesting. Such transactions are common and generally do not reflect a change in the executive's confidence in the company's long-term prospects. Therefore, it provides no new fundamental information to alter an existing investment thesis, warranting a 'hold' recommendation based solely on this filing.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Jolanda Howe, Corporate Governance